Reuters logo
BRIEF-Inovio’s cancer immunotherapy slowed PSA rise and increased PSA doubling times in patients with recurrent prostate cancer
September 11, 2017 / 12:33 PM / 3 months ago

BRIEF-Inovio’s cancer immunotherapy slowed PSA rise and increased PSA doubling times in patients with recurrent prostate cancer

Sept 11 (Reuters) - Inovio Pharmaceuticals Inc

* Inovio’s cancer immunotherapy (ino-5150) slowed PSA rise and significantly increased psa doubling times in patients with recurrent prostate cancer

* Inovio Pharmaceuticals - ‍interim data analysis showed ino-5150 cancer immunotherapy product generated antigen-specific CD8+ killer t cell responses​

* Inovio Pharma- ‍immunology results demonstrate ino-5150 treatment as monotherapy generated prostate specific antigen,prostate specific membrane antigen​

* Inovio Pharmaceuticals - ‍patients with specific cd8+ t cell responses experienced dampening in rise of psa, significant increases in psa doubling times​

* Inovio Pharma- ‍antigen-specific CD8+ killer t cell responses measured in peripheral blood from subjects with biochemically recurrent prostate cancer​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below